NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis $9.87 +0.43 (+4.56%) As of 12:21 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Atara Biotherapeutics Stock (NASDAQ:ATRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atara Biotherapeutics alerts:Sign Up Key Stats Today's Range$9.07▼$9.8750-Day Range$7.71▼$10.2352-Week Range$3.92▼$19.15Volume23,186 shsAverage Volume672,143 shsMarket Capitalization$99.08 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Atara Biotherapeutics, Inc. is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer, autoimmune diseases and other serious conditions. Its platform uses T cells derived from healthy donors and engineered or selected to recognize disease-associated targets, with the goal of creating “off-the-shelf” treatments that can be administered without collecting and manufacturing a patient’s own cells. The company’s leading product is tabelecleucel, marketed as Ebvallo, an allogeneic T-cell therapy designed to target Epstein-Barr virus-positive cells. Ebvallo has been approved in the United States and European Union for certain patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a rare and potentially life-threatening complication that can occur after organ or stem-cell transplantation. Atara has also investigated its platform in multiple sclerosis and other immune-mediated diseases, as well as additional oncology indications. Founded in 2012, Atara has operated internationally through clinical development, regulatory and commercial activities in North America and Europe. The company has collaborated with external partners to support the development, manufacturing and commercialization of its therapies. Pascal Touchon has served as Atara’s president and chief executive officer, although leadership and corporate arrangements may change as the company’s business develops.AI Generated. May Contain Errors. Read More Atara Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreATRA MarketRank™: Atara Biotherapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 688th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingModerate Buy Consensus RatingAtara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Atara Biotherapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAtara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($0.22) to $1.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -8.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Atara Biotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.24% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 11.07, which indicates bearish sentiment.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 10.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.10 News SentimentAtara Biotherapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atara Biotherapeutics this week, compared to 6 articles on an average week.Search Interest1 people have searched for ATRA on MarketBeat in the last 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $959,093.00 in company stock, which represents 0.9953% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have bought 2,344.91% more of their company's stock than they have sold. Specifically, they have bought $999,994.00 in company stock and sold $40,901.00 in company stock.Percentage Held by Insiders41.20% of the stock of Atara Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRA Stock News HeadlinesAtara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Above 50-Day Moving Average - What's Next?September 12, 2026 | americanbankingnews.comAtara Biotherapeutics (NASDAQ:ATRA) Director Brian Cherry Acquires 104,166 SharesSeptember 5, 2026 | insidertrades.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 16 at 1:00 AM | Stansberry Research (Ad)Atara Biotherapeutics (NASDAQ:ATRA) CEO Sells 5,062 Shares of StockAugust 27, 2026 | insidertrades.comAtara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational ProgressAugust 12, 2026 | finance.yahoo.comAtara Biotherapeutics Announces $15 Million Registered Direct OfferingJuly 7, 2026 | businesswire.comQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic LeukemiaJune 11, 2026 | globenewswire.comAtara Biotherapeutics Inc (ATRA)May 31, 2026 | investing.comSee More Headlines ATRA Stock Analysis - Frequently Asked Questions How have ATRA shares performed this year? Atara Biotherapeutics' stock was trading at $18.09 at the beginning of the year. Since then, ATRA shares have decreased by 46.9% and is now trading at $9.60. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its earnings results on Wednesday, August, 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.01. The biotechnology company had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.55 million. Atara Biotherapeutics had a negative net margin of 269.42% and a negative trailing twelve-month return on equity of 79.12%. When did Atara Biotherapeutics' stock split? Atara Biotherapeutics's stock reverse split on Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Atara Biotherapeutics IPO? Atara Biotherapeutics (ATRA) raised $75 million in an IPO on Thursday, October 16th 2014. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and FuelCell Energy (FCEL). Company Calendar Last Earnings8/12/2026Today9/16/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, ATRA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATRA CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees330Year Founded2012Price Target and Rating Average Price Target for Atara Biotherapeutics$9.50 High Price Target$13.00 Low Price Target$6.00 Potential Upside/Downside-3.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$32.69 million Net Margins-269.42% Pretax Margin-268.95% Return on Equity-79.12% Return on Assets-73.01% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.98 Sales & Book Value Annual Sales$6.19 million Price / Sales16.00 Cash Flow$5.19 per share Price / Cash Flow1.90 Book Value($5.34) per share Price / Book-1.85Miscellaneous Outstanding Shares10,038,000Free Float5,902,000Market Cap$99.08 million OptionableNo Data Beta0.10 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ATRA) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
